Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume 25, 2024 - Issue 1-2
Biomarkers
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial
Jeremy M. Shefner1 Barrow Neurological Institute, University of Arizona, and Creighton University, Phoenix, AZ, USA andCorrespondence[email protected]
https://orcid.org/0000-0001-5067-5602
https://orcid.org/0000-0001-5067-5602, Bill Jacobsen1 Barrow Neurological Institute, University of Arizona, and Creighton University, Phoenix, AZ, USA andhttps://orcid.org/0009-0009-8722-1888
https://orcid.org/0009-0009-8722-1888, Stuart Kupfer2 Cytokinetics, Incorporated, South San Francisco, CA, USAhttps://orcid.org/0000-0002-5469-1287
https://orcid.org/0000-0002-5469-1287, Fady I. Malik2 Cytokinetics, Incorporated, South San Francisco, CA, USAhttps://orcid.org/0000-0002-5597-5759
https://orcid.org/0000-0002-5597-5759, , , Andrew A Wolff2 Cytokinetics, Incorporated, South San Francisco, CA, USAhttps://orcid.org/0000-0002-9094-0359
https://orcid.org/0000-0002-9094-0359 & Stacy A. Rudnicki2 Cytokinetics, Incorporated, South San Francisco, CA, USAhttps://orcid.org/0000-0002-3499-5208
https://orcid.org/0000-0002-3499-5208 show all